Ascendiant Capital maintains Aemetis at Buy, lowers price target to $18 from $20
Ascendiant Capital retained its Buy rating for Aemetis but reduced its price target from $20 to $18, a 10% cut. The new target suggests a 1400% upside from the Nov 13 close of $1.20, according to the firm.






